Immuneering Corp Cl A (IMRX)

$4.14 -0.08 (-1.90%)
Market Cap 272.49M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,567,400
Avg Vol 1,881,036
Day's Range N/A - N/A
Shares Out 64.57M
Stochastic %K 2%
Beta 0.48
Analysts Strong Sell
Price Target $16.83

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
Thian
Thian Jan. 14 at 2:11 PM
$IMRX Volume and up in premarket. Good sign.
0 · Reply
Cheaslea76
Cheaslea76 Jan. 14 at 1:49 PM
$IMRX
0 · Reply
AZOZ
AZOZ Jan. 14 at 1:28 PM
$IMRX Insider activity!
0 · Reply
kdmack116
kdmack116 Jan. 14 at 1:25 PM
SEC Filing | Immuneering Corporation. $IMRX https://ir.immuneering.com/node/9166/html
0 · Reply
kdmack116
kdmack116 Jan. 14 at 1:22 PM
$IMRX insider buy on January 12. They paid $4.34
1 · Reply
Captenotwo
Captenotwo Jan. 14 at 1:21 PM
$IMRX I think the bottom is in. 👍👍 Cheers peeps Cap
0 · Reply
delaydeal
delaydeal Jan. 14 at 5:14 AM
$IMRX Short seller`s playing!
0 · Reply
RUDYRUDY
RUDYRUDY Jan. 14 at 1:26 AM
$IMRX Total dumpster fire…..no dead cat bounce, just straight down.
1 · Reply
Wolfmantis
Wolfmantis Jan. 14 at 12:02 AM
$IMRX there will be a summit like gap up after the totality data , large quantity of accumulation these last few days.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Jan. 13 at 9:27 PM
$IMRX Sanofi was the buyer but Oppenheimer is the book runner. Sanofi currently down -$13,716,000 on their investment. Does anyone know the duration of their lockup period?
1 · Reply
Latest News on IMRX
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

Jan 8, 2026, 5:45 PM EST - 5 days ago

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Jan 8, 2026, 9:28 AM EST - 5 days ago

Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript

Jan 7, 2026, 6:47 PM EST - 6 days ago

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Jan 7, 2026, 4:00 PM EST - 6 days ago

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Dec 23, 2025, 8:00 AM EST - 22 days ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 17, 2025, 4:05 PM EST - 27 days ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 16, 2025, 8:00 AM EST - 4 weeks ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 7 weeks ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 9:11 PM EST - 2 months ago

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 12, 2025, 4:05 PM EST - 2 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Nov 4, 2025, 4:05 PM EST - 2 months ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Immuneering Corporation - Special Call

Sep 29, 2025, 4:37 PM EDT - 3 months ago

Immuneering Corporation - Special Call

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 26, 2025, 4:01 PM EDT - 3 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 2:19 PM EDT - 3 months ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 25, 2025, 12:08 AM EDT - 3 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 3 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 24, 2025, 4:01 PM EDT - 3 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 16, 2025, 7:00 AM EDT - 4 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 10, 2025, 7:00 AM EDT - 4 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering Announces Closing of $25 Million Private Placement

Aug 26, 2025, 4:05 PM EDT - 5 months ago

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Aug 25, 2025, 8:00 AM EDT - 5 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Immuneering Announces $25 Million Private Placement

Aug 21, 2025, 8:00 AM EDT - 5 months ago

Immuneering Announces $25 Million Private Placement

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 5 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jul 9, 2025, 8:00 AM EDT - 6 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 17, 2025, 6:00 AM EDT - 7 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 16, 2025, 8:00 AM EDT - 7 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 8 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 4:05 PM EDT - 9 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 10 months ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 4:05 PM EDT - 10 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 10 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 1 year ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Dec 13, 2024, 2:10 PM EST - 1 year ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Thian
Thian Jan. 14 at 2:11 PM
$IMRX Volume and up in premarket. Good sign.
0 · Reply
Cheaslea76
Cheaslea76 Jan. 14 at 1:49 PM
$IMRX
0 · Reply
AZOZ
AZOZ Jan. 14 at 1:28 PM
$IMRX Insider activity!
0 · Reply
kdmack116
kdmack116 Jan. 14 at 1:25 PM
SEC Filing | Immuneering Corporation. $IMRX https://ir.immuneering.com/node/9166/html
0 · Reply
kdmack116
kdmack116 Jan. 14 at 1:22 PM
$IMRX insider buy on January 12. They paid $4.34
1 · Reply
Captenotwo
Captenotwo Jan. 14 at 1:21 PM
$IMRX I think the bottom is in. 👍👍 Cheers peeps Cap
0 · Reply
delaydeal
delaydeal Jan. 14 at 5:14 AM
$IMRX Short seller`s playing!
0 · Reply
RUDYRUDY
RUDYRUDY Jan. 14 at 1:26 AM
$IMRX Total dumpster fire…..no dead cat bounce, just straight down.
1 · Reply
Wolfmantis
Wolfmantis Jan. 14 at 12:02 AM
$IMRX there will be a summit like gap up after the totality data , large quantity of accumulation these last few days.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Jan. 13 at 9:27 PM
$IMRX Sanofi was the buyer but Oppenheimer is the book runner. Sanofi currently down -$13,716,000 on their investment. Does anyone know the duration of their lockup period?
1 · Reply
Coromina
Coromina Jan. 13 at 8:29 PM
$IMRX That's disgusting, oh my God.
0 · Reply
Captenotwo
Captenotwo Jan. 13 at 8:20 PM
$IMRX haters keep hating here. It will stop at some point. 😱
0 · Reply
Thian
Thian Jan. 13 at 8:12 PM
$IMRX Low volume today, compared to the last days. Nearly flat after a new low. Signs, that sellers are exhausted. Good chances, we start to go up from here.
0 · Reply
Annet_why_net
Annet_why_net Jan. 13 at 7:50 PM
$IMRX Reading some of the comments made me curious... Interesting perspective. I’m just trying to understand — how would you classify a move from $8.50 to $4 if not a sell-off? 🙃
0 · Reply
Coromina
Coromina Jan. 13 at 7:34 PM
$IMRX What's clear is that there's something very, very bad going on behind the scenes that they don't want to tell us or explain... no one is taking responsibility or explaining anything... in other words, SCAMMERS and liars.
1 · Reply
JuggernautRaider
JuggernautRaider Jan. 13 at 7:15 PM
$IMRX holding long 💪
0 · Reply
kdmack116
kdmack116 Jan. 13 at 7:01 PM
$IMRX I’m long but what boring price action! Let’s go. Enough with the mark downs!
0 · Reply
Annet_why_net
Annet_why_net Jan. 13 at 5:03 PM
$IMRX I hope this is now complete, as it took longer than anticipated. I am awaiting confirmation regarding the conclusion of the sale😏
5 · Reply
Coromina
Coromina Jan. 13 at 5:00 PM
$IMRX green…oh my good🤪
0 · Reply
Bwnuts
Bwnuts Jan. 13 at 4:34 PM
$ALGS $IMRX has a better chance of significant return than $ALGS IN 2026.
0 · Reply
CEM97
CEM97 Jan. 13 at 4:09 PM
$IMRX almost buy time
0 · Reply
OptimistJP
OptimistJP Jan. 13 at 4:03 PM
$IMRX The longer this continues without comment by Oppenheimer, the more I am forced to conclude they are complicent.
0 · Reply